Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Hrepić, Darijo"'
Autor:
Božanić, Ana, Šegota, Doris, Debeljuh, Dea Dundara, Kolacio, Manda Švabić, Radojčić, Đeni Smilović, Ružić, Katarina, Budanec, Mirjana, Kasabašić, Mladen, Hrepić, Darijo, Valković Zujić, Petra, Brambilla, Marco, Kalra, Mannudeep K., Jurković, Slaven
Publikováno v:
In Physica Medica April 2022 96:123-129
Autor:
Petrović Borislava S., Faj Dario Z., Marković Mladen B., Tot Arpad A., Marjanović Milana S., Kasabašić Mladen D., Gencel Ivan V., Paunović Dragomir R., Stanković Jelena V., Krestić-Vesović Jelena, Mišković Ivana M., Čičarević Koča B., Bibić Juraj I., Budanec Mirjana S., Kralik Ivana T., Galić Stipe J., Hrepić Darijo S., Ibrišimović Lejla A., Davidović Jasna Đ., Kolarević Goran D.
Publikováno v:
Nuclear Technology and Radiation Protection, Vol 36, Iss 1, Pp 97-106 (2021)
The purpose of this work was to evaluate computed tomography simulators used in radio-therapy treatment planning in Serbia, Croatia, and Bosnia and Herzegovina. A survey of quality assurance programmes of 24 computed tomography simulators in 16 facil
Externí odkaz:
https://doaj.org/article/70438f8a477f481e875dccff7be7a166
Autor:
Petrić-Miše, Branka, Katalenić, Monika, Hrepić, Darijo, Kuret, Sendi, Drmić-Hofman, Irena, Tomić, Snježana
Publikováno v:
Libri Oncologici : Croatian Journal of Oncology
Volume 51
Issue 1
Volume 51
Issue 1
Aim: To investigate the clinical and pathohistological tumor characteristics, treatment, and treatment outcomes in patients with hereditary breast and ovarian cancer who were diagnosed, treated, and monitored at the University Hospital of Split from
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Libri Oncologici : Croatian Journal of Oncology
Volume 50
Issue 1
Volume 50
Issue 1
Aim: To evaluate the treatment outcomes, with emphasis on the efficacy and safety of olaparib, in patients with platinum-sensitive, BRCA-mutated, recurrent ovarian cancer treated at the University Hospital Center Split in the period from June 2016 to
Autor:
Majić, Ana, Urlić, Ivan, Pancirov, Marija, Paparella - Karaman, Ana, Strikić, Ante, Ban, Marija, Hrepić, Darijo, Vrdoljak, Eduard
Hematotoxicity od cyclin dependent kynases 4/6 (CDK4/6) inhibitors palbociclib and ribocyclib during first 2 cycles of treatment of metastatic breast cancer – a restropective analysis in single centre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::66c54b2c5c93ee703e3c7eff3d2f028d
https://www.bib.irb.hr/1258989
https://www.bib.irb.hr/1258989
Retrospektivna analiza trifluridine tipiracilom na Klinici za onkologiju i radioterapiju KBC Split.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::29227cf4bc1fc2885feca1d3e651659f
https://www.bib.irb.hr/1158278
https://www.bib.irb.hr/1158278
Autor:
Bošković, Lidija, Hrepić, Darijo, Viculin, Jelena, Boraska Jelavić, Tihana, Boban, Marijo, Omrčen, Tomislav, Vrdoljak, Eduard
Background: Immunotherapy has demonstrated promising results in cancer patients. Immune checkpoint inhibition with the anti- PD-1 antibody nivolumab has improved survival in metastatic lung cancer, renal cancer and melanoma patients. The toxicity pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::16b69a917f04a0638c8a069cc37da17f
https://www.bib.irb.hr/1158274
https://www.bib.irb.hr/1158274
Background: Immunotherapy has demonstrated promising results in cancer patients. In phase III randomised trial (CheckMate 025 trial) immune checkpoint inhibition with the anti- PD-1 antibody nivolumab prolonged overall survival as compared with evero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::1c27e85dbcb000903dc9cb150372f959
https://www.bib.irb.hr/1158273
https://www.bib.irb.hr/1158273
Introduction: Metastatic castration resistant prostate cancer (mCRPC) is defined as disease progression, biochemically or radiologically, despite castrate levels of testosterone. The therapeutic armamentarium available today has allowed for extension
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::636ea03d7f91456a60a6cf2c6bcec641
https://www.bib.irb.hr/1158271
https://www.bib.irb.hr/1158271